Dosing and administration

For adult and adolescent patients ≥12 years of age

Dosing options that fit patients' HAE needs

The TAKHZYRO prefilled syringe lets patients control the speed of injection1

2 subcutaneous injections per month1,2†

OR

1 subcutaneous injections per month1,2†

TAKHZYRO (lanadelumab-flyo) prefilled syringe

TAKHZYRO (lanadelumab-flyo) prefilled syringe

The recommended starting dosage is
one 300 mg/2 mL injection every 2 weeks­1

TAKHZYRO (lanadelumab-flyo) prefilled syringe Not actual size.

If the patient has no attacks for >6 months,
one 300 mg/2 mL injection every 4 weeks may be considered1

†One month is defined as 28 days.2
All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.

Style
inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-bottom-padding, section-dosing

Remind your patients and their caregivers to always have acute treatment on hand and periodically check the date to ensure it hasn't expired.

Style
section-content-contained, background-green-light, rounded-corners

For pediatric patients 2 to <12 years of age

Longest-established HAE preventive option for ages 2+1,3–6

Approved for pediatric use in 2023

TAKHZYRO provides freedom from daily dosing

Style
inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-bottom-padding, section-dosing
For patients 2 to <6 years:

1 subcutaneous injections per month1,2†

TAKHZYRO (lanadelumab-flyo) prefilled syringe

(one 150 mg/1 mL injection
every 4 weeks)1

For patients 6 to <12 years:

2 subcutaneous injections per month1,2†

OR

1 subcutaneous injections per month1,2†

TAKHZYRO (lanadelumab-flyo) prefilled syringe

TAKHZYRO (lanadelumab-flyo) prefilled syringe

(two 150 mg/1 mL injections
every 2 weeks)1

TAKHZYRO (lanadelumab-flyo) prefilled syringe Not actual size.

If the patient has no attacks for >6
months, one 300 mg/2 mL injection every 4 weeks may be considered1

Style
inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-bottom-padding, section-dosing, section-dosing-flex-tak

†One month is defined as 28 days.2

Style
inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-bottom-padding

Prescribed to 130+ pediatric patients as young as 2 years of age since 2023,‡ TAKHZYRO may be an option for your patients and their family members with HAE.7

Style
section__content-contained, section-no-bottom-margin, background-yellow-light, rounded-corners

‡Based on third-party US specialty pharmacy data.

27-gauge, 0.5-inch needle

The TAKHZYRO prefilled syringe is a smaller gauge than other subcutaneous injections, such as those used for1,8,9

  • Vaccinations (22-25 gauge, 1-1.5 inches)8
  • FIRAZYR® (icatibant [25 gauge, 0.625 inch])9

The TAKHZYRO prefilled syringe does not require reconstitution.1

Style
inner-content-contained, section-bottom-32-margin, section-no-top-margin, section-no-top-padding, section-no-bottom-padding, section-dosing-image

Takeda Patient Support—support specialists your patient can count on

When you prescribe a Takeda treatment for your patient, Takeda Patient Support is here for them.

ENROLL YOUR PATIENT

Style
background-lavender-light, inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-dosing-patient

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2025. 2. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773 3. Cinryze. Prescribing information. Takeda Pharmaceuticals USA, Inc; 2023. 4. Haegarda. Prescribing information. CSL Behring LLC; 2022. 5. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc; 2022. 5. Dawnzera. Prescribing information. Ionis Pharmaceuticals, Inc; 2025. 6. Andembry. Prescribing information. CSL Behring LLC; 2025. 7. Data on File. Takeda Pharmaceuticals. 8. Vaccine administration. Centers for Disease Control and Prevention. Updated June 20, 2023. Accessed May 23, 2024. http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html 9. Firazyr. Prescribing information. Takeda Pharmaceuticals USA, Inc; 2024.

Style
inner-content-contained, section-no-bottom-margin, section-no-top-margin, section-references
https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi
Style
Inner-content-contained, section-no-margin
id
important-safety-information